

**PRESCRIBING INFORMATION:** See Summary of Product Characteristics before prescribing

**Priorix** Measles, mumps and rubella vaccine (live). **Composition:** Lyophilised measles-mumps-rubella component as powder with clear solvent for reconstitution. **Uses:** Active immunisation against measles, mumps and rubella, of individuals from age of 9 months. **Dosage and Administration:** 0.5mls should be injected subcutaneously. May be given i.m (deltoid or anterolateral area of thigh). A second dose may be given according to official recommendations - for ages 9-12 months, second dose recommended 4-12 weeks after initial dose. Use separate injection site if simultaneously using other vaccines, or leave interval of at least one month for live vaccines. **Adverse Reactions:** See SPC for full details. *Very common:* Injection site redness; fever  $\geq 38^{\circ}\text{C}$  (rectal) or  $\geq 37.5^{\circ}\text{C}$  (axillary/oral). *Common:* Upper respiratory tract infection; rash; injection site pain and swelling; fever  $\geq 39.5^{\circ}\text{C}$  (rectal) or  $\geq 39^{\circ}\text{C}$  (axillary/oral). *Serious:* Febrile convulsions (rare), meningitis, orchitis, epididymitis, thrombocytopenia, anaphylaxis, neurological disorders including Guillain Barré syndrome. **Contraindications:** Hypersensitivity to any component of the vaccine or neomycin, severe immunodeficiency, pregnancy, acute severe febrile illness. **Precautions:** Use with caution in those with CNS disorder, family history or susceptibility to febrile convulsions and those who have allergy to egg products. Limited protection possible if used within 72 hours of exposure to measles. DO NOT administer intravascularly. Consider risk:benefit for those with thrombocytopenia as condition may worsen, and for those with selected immune deficiencies. Delay use in subjects receiving human gamma globulins or blood transfusions. Avoid pregnancy for one month following vaccination. Evaluate risk:benefit if vaccinating mother of breast-feeding immunodeficient infant. **Legal Category:** POM MA number: PL/10592/0110 NHS Cost: £7.64 MA Holder: SmithKline Beecham Ltd, Great West Road, Brentford, Middlesex, TW8 9GS. **Further information is available from:** The GSK Customer Contact Centre: customercontactuk@gsk.com; Freephone 0800 221 441

**Date of preparation:** May 2020

**Ref:** PI-0512 (V2.0)

**Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard), or search for MHRA yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.**